Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Augmentation of antitumor immunity by fusions of ethanol-treated tumor cells and dendritic cells stimulated via dual TLRs through TGF-β1 blockade and IL-12p70 production.

Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Takahara A, Odahara S, Tsukinaga S, Yukawa T, Mitobe J, Matsudaira H, Nagatsuma K, Kajihara M, Uchiyama K, Arihiro S, Imazu H, Arakawa H, Kan S, Hayashi K, Komita H, Kamata Y, Ito M, Hara E, Ohkusa T, Gong J, Tajiri H.

PLoS One. 2013 May 24;8(5):e63498. doi: 10.1371/journal.pone.0063498. Print 2013.

2.

Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes.

Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Takahara A, Odahara S, Tsukinaga S, Yukawa T, Mitobe J, Matsudaira H, Nagatsuma K, Uchiyama K, Kajihara M, Arihiro S, Imazu H, Arakawa H, Kan S, Komita H, Ito M, Ohkusa T, Gong J, Tajiri H.

PLoS One. 2013;8(3):e59280. doi: 10.1371/journal.pone.0059280. Epub 2013 Mar 15.

3.

Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells.

Koido S, Hara E, Homma S, Mitsunaga M, Takahara A, Nagasaki E, Kawahara H, Watanabe M, Toyama Y, Yanagisawa S, Kobayashi S, Yanaga K, Fujise K, Gong J, Tajiri H.

J Immunol. 2007 Oct 1;179(7):4874-83.

4.

In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells.

Koido S, Homma S, Hara E, Mitsunaga M, Namiki Y, Takahara A, Nagasaki E, Komita H, Sagawa Y, Ohkusa T, Fujise K, Gong J, Tajiri H.

J Transl Med. 2008 Sep 15;6:51. doi: 10.1186/1479-5876-6-51.

5.

Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells.

Koido S, Hara E, Homma S, Torii A, Mitsunaga M, Yanagisawa S, Toyama Y, Kawahara H, Watanabe M, Yoshida S, Kobayashi S, Yanaga K, Fujise K, Tajiri H.

J Immunol. 2007 Jan 1;178(1):613-22.

6.

Engagement of human monocyte-derived dendritic cells into interleukin (IL)-12 producers by IL-1beta + interferon (IFN)-gamma.

Nakahara T, Urabe K, Fukagawa S, Uchi H, Inaba K, Furue M, Moroi Y.

Clin Exp Immunol. 2005 Mar;139(3):476-82.

7.

Efficient CTL productivity of modified fusion cells by increase of heat shock protein 70.

Koide T, Iinuma H, Fukushima R.

Oncol Rep. 2009 Mar;21(3):737-46.

PMID:
19212634
8.

Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.

Bohnenkamp HR, Coleman J, Burchell JM, Taylor-Papadimitriou J, Noll T.

Cell Immunol. 2004 Sep-Oct;231(1-2):112-25. Epub 2005 Feb 8.

PMID:
15919376
10.

Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.

Kontani K, Teramoto K, Ozaki Y, Sawai S, Tezuka N, Ishida H, Kajino K, Fujino S, Yamauchi A, Taguchi O, Kannagi R, Yokomise H, Ogasawara K.

Oncol Rep. 2007 Apr;17(4):895-902.

PMID:
17342333
11.
12.

Enhancement of Anti-Leukemia Immunity by Leukemia-Derived Exosomes Via Downregulation of TGF-β1 Expression.

Huang F, Wan J, Hu W, Hao S.

Cell Physiol Biochem. 2017;44(1):240-254. doi: 10.1159/000484677. Epub 2017 Nov 9.

13.

Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.

Pham TN, Hong CY, Min JJ, Rhee JH, Nguyen TA, Park BC, Yang DH, Park YK, Kim HR, Chung IJ, Kim HJ, Lee JJ.

Exp Mol Med. 2010 Jun 30;42(6):407-19.

14.

Induction of antigen-specific cytotoxic T lymphocytes by fusion cells generated from allogeneic plasmacytoid dendritic and tumor cells.

Koido S, Homma S, Kan S, Takakura K, Namiki Y, Kobayashi H, Ito Z, Uchiyama K, Kajihara M, Arihiro S, Arakawa H, Okamoto M, Ohkusa T, Gong J, Tajiri H.

Int J Oncol. 2014 Jul;45(1):470-8. doi: 10.3892/ijo.2014.2433. Epub 2014 May 9. Erratum in: Int J Oncol. 2015 Jun;46(6):2679.

PMID:
24819411
15.

Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.

Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A.

Cancer Res. 2001 Nov 1;61(21):7925-33.

16.

Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy.

Feili-Hariri M, Falkner DH, Morel PA.

J Leukoc Biol. 2005 Sep;78(3):656-64. Epub 2005 Jun 16.

PMID:
15961574
17.
18.

Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy.

Lim SN, Kuhn S, Hyde E, Ronchese F.

J Immunother. 2012 Nov-Dec;35(9):670-9. doi: 10.1097/CJI.0b013e318270e135.

PMID:
23090076
19.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645

Supplemental Content

Support Center